Abstract Search

impe0096p82 | GH and IGFs | IMPE2023

Children with Growth Hormone Deficiency Who Completed Treatment with Lonapegsomatropin Approached or Exceeded Average Parental Height at Week 130 in the enliGHten Trial

Thornton Paul , Hofman Paul , Nadgir Ulhas , Saenger Paul , Chertok Elena , Aghajanova Elena , Song Wenjie , Mao Meng , Komirenko Allison , Beckert Michael , Shu Aimee , Maniatis Aristides

Background: Lonapegsomatropin (TransCon hGH) is a once-weekly prodrug of somatropin, approved for the treatment of pediatric growth hormone deficiency (pGHD) by the US FDA and EMA. In the pivotal phase 3 heiGHt trial, lonapegsomatropin demonstrated noninferior and superior annualized heigh velocity (AHV) and a comparable safety profile to daily somatropin in children with GHD. The ongoing open-label extension trial, enliGHten, enrolled participants from the he...

2 shares

IMPE Abstracts

Children with Growth Hormone Deficiency Who Completed Treatment with Lonapegsomatropin Approached or Exceeded Average Parental Height at Week 130 in the enliGHten Trial

BiosciAbstracts